These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35287160)

  • 21. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
    Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnesium-based bioresorbable scaffolds in STEMI. The quest for the optimal bioresorption balance.
    Gonzalo N; McInerney A
    EuroIntervention; 2020 Dec; 16(11):e869-e871. PubMed ID: 33274723
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-Term Clinical Outcomes of Biodegradable-Polymer Drug-Eluting Stents Versus Second-Generation Durable-Polymer Drug-Eluting Stents for ST-Segment Elevation Myocardial Infarction.
    Sim HW; Thong EH; Djohan AH; Chen JZ; Ser JS; Loh PH; Lee CH; Chan MY; Low AF; Tay EL; Chan KH; Tan HC; Loh JP
    Cardiovasc Revasc Med; 2022 Feb; 35():98-103. PubMed ID: 33893053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Five-year clinical outcomes and intracoronary imaging findings of the COMFORTABLE AMI trial: randomized comparison of biodegradable polymer-based biolimus-eluting stents with bare-metal stents in patients with acute ST-segment elevation myocardial infarction.
    Räber L; Yamaji K; Kelbæk H; Engstrøm T; Baumbach A; Roffi M; von Birgelen C; Taniwaki M; Moschovitis A; Zaugg S; Ostojic M; Pedrazzini G; Karagiannis-Voules DA; Lüscher TF; Kornowski R; Tüller D; Vukcevic V; Heg D; Windecker S
    Eur Heart J; 2019 Jun; 40(24):1909-1919. PubMed ID: 30851032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report.
    Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ
    Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioresorbable scaffold implantation in STEMI patients: 5 years imaging subanalysis of PRAGUE-19 study.
    Kočka V; Toušek P; Kozel M; Buono A; Hajšl M; Lisa L; Buděšínský T; Malý M; Widimský P
    J Transl Med; 2020 Jan; 18(1):33. PubMed ID: 32000796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
    Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
    JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-Scaffold Neovascularization 24 Months After Bioresorbable Vascular Scaffold Implantation in a Patient With ST-Segment Elevation Myocardial Infarction.
    Tomaniak M; Kochman J; Kołtowski Ł; Pietrasik A; Rdzanek A; Filipiak KJ; Opolski G; Regar E
    JACC Cardiovasc Interv; 2017 Jul; 10(13):e123-e125. PubMed ID: 28624381
    [No Abstract]   [Full Text] [Related]  

  • 29. Differential thrombotic prolapse burden in either bioresorbable vascular scaffolds or metallic stents implanted during acute myocardial infarction: The snowshoe effect: Insights from the maximal footprint analysis.
    Diletti R; van der Sijde J; Karanasos A; Fam JM; Felix C; van Mieghem NM; Regar E; Rapoza R; Zijlstra F; van Geuns RJ
    Int J Cardiol; 2016 Oct; 220():802-8. PubMed ID: 27394977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data.
    Cassese S; Katagiri Y; Byrne RA; Brugaletta S; Alfonso F; Räber L; Maeng M; Iñiguez A; Kretov E; Onuma Y; Joner M; Sabaté M; Laugwitz KL; Windecker S; Kastrati A; Serruys PW
    EuroIntervention; 2020 Mar; 15(16):1451-1457. PubMed ID: 30719976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
    Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Valgimigli M; Windecker S; Pilgrim T
    Int J Cardiol; 2021 Jul; 334():37-41. PubMed ID: 33887341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of bioresorbable vascular scaffolds versus cobalt-chromium everolimus-eluting stent in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a review of currently available clinical data.
    Buccheri D; Piraino D; Chirco PR; Cortese B
    Minerva Cardioangiol; 2016 Feb; 64(1):74-83. PubMed ID: 26447989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold.
    Wiebe J; Möllmann H; Most A; Dörr O; Weipert K; Rixe J; Liebetrau C; Elsässer A; Achenbach S; Hamm C; Nef H
    Clin Res Cardiol; 2014 Feb; 103(2):141-8. PubMed ID: 24136291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold.
    Kochman J; Kołtowski Ł; Tomaniak M; Jąkała J; Proniewska K; Legutko J; Roleder T; Piertrasik A; Rdzanek A; Kochman W; Brugaletta S; Opolski G; Regar E
    EuroIntervention; 2018 Apr; 13(18):e2201-e2209. PubMed ID: 29155384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study.
    Widimsky P; Petr R; Tousek P; Maly M; Linkova H; Vrana J; Hajsl M; Budesinsky T; Lisa L; Kocka V
    Circ Cardiovasc Interv; 2015 Dec; 8(12):e002933. PubMed ID: 26628591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design.
    Brugaletta S; Cequier A; Alfonso F; Iñiguez A; Romaní S; Serra A; Salinas P; Goicolea J; Bordes P; Del Blanco BG; Hernández-Antolín R; Pernigotti A; Gómez-Lara J; Sabaté M
    Catheter Cardiovasc Interv; 2019 Jan; 93(1):64-70. PubMed ID: 30196572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ST-segment elevation myocardial infarction – ideal scenario for bioresorbable vascular scaffold implantation?
    Scalone G; Brugaletta S; Gómez-Monterrosas O; Otsuki S; Sabate M
    Circ J; 2015; 79(2):263-70. PubMed ID: 25744740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year follow-up after bioresorbable vascular scaffold implantation in STEMI patients - Results from PRAGUE-19 study.
    Toušek P; Kočka V; Malý M; Kozel M; Robert P; Hajšl M; Jarkovský J; Widimský P
    Int J Cardiol; 2016 Apr; 209():20-1. PubMed ID: 26878467
    [No Abstract]   [Full Text] [Related]  

  • 40. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.